Alexander C. Egilman

Jun 5, 2024 | dialnet.unirioja.es | Alexander C. Egilman |Aaron S. Kesselheim |Jerry Avorn |Adam J. N

Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque PsoriasisAutores: Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn, Adam J. N. Raymakers, Benjamin N. RomeLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 4, 2024, págs. 409-416Idioma: inglésEnlacesTexto completoResumenImportance The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles.

May 20, 2024 | jamanetwork.com | Alexander C. Egilman |Aaron S. Kesselheim

Abstract Importance  The Federal Trade Commission’s (FTC) oversight role in the pharmaceutical market is critical to the health of patients and the health care system. This study characterized the FTC’s policy on the pharmaceutical market in recent decades, identifying the types of actions it has favored, barriers it has faced, and authorities that remain untested. Objective  To review FTC legal actions in the pharmaceutical market from 2000-2022.

Feb 21, 2024 | jamanetwork.com | Alexander C. Egilman |Aaron S. Kesselheim |Jerry Avorn

Key PointsQuestion  How could an efficiency frontier approach be used to better align prices with the clinical efficacy of biologic medications for plaque psoriasis? Findings  In this economic evaluation, US net prices of 13 biologic therapies for psoriasis ranged from $1664 to $79 277 per year, and clinical efficacy measured by Psoriasis Area Severity Index 90 scores ranged from 17.9% to 71.6%.

Aug 15, 2023 | jamanetwork.com | Alexander C. Egilman |Aaron S. Kesselheim

Gauging the Value of Top-Selling Drugs in Medicare—Reply In Reply In our recent article,1 we found that a majority of Medicare’s top-selling drugs received low added therapeutic benefit ratings by health technology assessment (HTA) organizations in France, Germany, and Canada.